Mallory Morales
Known title: Chief Accounting OfficerCIK: 0001941795
Mallory Morales's purchase track record
Mallory Morales has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/1/2025 | IMRX | $2K | +3.5% | -16.2% | -2.0% |
| 3/21/2024 | IMRX | $4K | -48.4% | -11.4% | +9.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMRX | ▲ Buy | Open Market | 300 | $2K | 10/1/2025 | View on chart |
| IMRX | ▲ Buy | Grant | 14,497 | $21K | 9/15/2025 | View on chart |
| IMRX | ▲ Buy | Grant | 4,458 | $7K | 9/15/2024 | View on chart |
| IMRX | ▲ Buy | Open Market | 393 | $1K | 3/22/2024 | View on chart |
| IMRX | ▲ Buy | Open Market | 1,107 | $3K | 3/21/2024 | View on chart |
| IMRX | ▲ Buy | Grant | 4,344 | $7K | 3/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Immuneering to Present Data at ESMO Congress 2026
Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.
Immuneering to Present Data at ESMO Congress 2026. Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.